KG&L Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

KG&L Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,011	Closed	-$703K	–	139
2025 Q4	$703K	Sell	13,011 -10,588	-45%	-$509K	0.17%	111
2025 Q3	$1.07M	Sell	23,599 -23,052	-49%	-$1.08M	0.29%	79
2025 Q2	$2.16M	Buy	46,651 +39,136	+521%	+$1.92M	0.64%	39
2025 Q1	$459K	Sell	7,515 -8,177	-52%	-$477K	0.15%	126
2024 Q4	$889K	Sell	15,692 -15,435	-50%	-$862K	0.29%	76
2024 Q3	$1.61M	Sell	31,127 -748	-2%	-$35.1K	0.52%	45
2024 Q2	$1.33M	Sell	31,875 -1,705	-5%	-$76.3K	0.46%	49
2024 Q1	$1.82M	Buy	33,580 +6,277	+23%	+$320K	0.72%	32
2023 Q4	$1.4M	Buy	27,303 +5,718	+26%	+$300K	0.59%	38
2023 Q3	$1.25M	Sell	21,585 -4,061	-16%	-$249K	0.61%	39
2023 Q2	$1.64M	Buy	25,646 +2,764	+12%	+$185K	0.79%	27
2023 Q1	$1.59M	Buy	22,882 +10,660	+87%	+$752K	0.83%	27
2022 Q4	$879K	Buy	12,222 +327	+3%	+$24.7K	0.51%	47
2022 Q3	$846K	Buy	11,895 +5,787	+95%	+$420K	0.48%	54
2022 Q2	$470K	Sell	6,108 -2,876	-32%	-$219K	0.25%	78
2022 Q1	$656K	Sell	8,984 -44,362	-83%	-$2.98M	0.27%	76
2021 Q4	$3.33M	Sell	53,346 -3,025	-5%	-$177K	1.34%	17
2021 Q3	$3.33M	Buy	56,371 +15,655	+38%	+$1.03M	1.46%	17
2021 Q2	$2.72M	Buy	40,716 +2,991	+8%	+$195K	1.24%	21
2021 Q1	$2.38M	Buy	37,725 +9,019	+31%	+$561K	1.19%	23
2020 Q4	$1.78M	Buy	28,706 +5,364	+23%	+$330K	0.97%	24
2020 Q3	$1.41M	Buy	23,342 +4,365	+23%	+$263K	0.88%	33
2020 Q2	$1.11M	Buy	18,977 +7,347	+63%	+$439K	0.86%	34
2020 Q1	$648K	Sell	11,630 -315	-3%	-$19.3K	0.64%	42
2019 Q4	$766K	Sell	11,945 -1,353	-10%	-$77.5K	0.65%	45
2019 Q3	$674K	Sell	13,298 -3,806	-22%	-$179K	0.61%	44
2019 Q2	$775K	Buy	17,104 +4,761	+39%	+$222K	0.74%	40
2019 Q1	$589K	Sell	12,343 -5,889	-32%	-$293K	0.59%	51
2018 Q4	$950K	Buy	+18,232	New	+$980K	1.06%	25

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KG&L Capital Management's BMY Position: Q1 2026 in Review

KG&L Capital Management sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 13,011 shares — an estimated $703K sold.

KG&L Capital Management first reported a position in BMY in Q4 2018 and held it in 29 quarters. The position peaked at $3.33M in Q3 2021. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

KG&L Capital Management reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
KG&L Capital Management sold 13,011 Bristol-Myers Squibb shares in Q1 2026, an estimated $703K.
KG&L Capital Management first reported a position in Bristol-Myers Squibb in Q4 2018 and held it in 29 quarters.
KG&L Capital Management's Bristol-Myers Squibb position peaked at $3.33M in Q3 2021.
2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on KG&L Capital Management's 13F filing for Q1 2026, filed 23 Apr 2026.